Takahiro Nunokawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takahiro Nunokawa has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Naofumi Chinen
Department of Internal Medicine, Tama Nambu Chiiki Hospital, Japan
4 shared publications- Naofumi Chinen
Department of Rheumatic Diseases, Tama-Nambu Chiiki Hospital, Tokyo, Japan
3 shared publications - Kota Shimada
Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo
2 shared publications Shino Sogabe
Department of Internal Medicine, Tama Nambu Chiiki Hospital, Japan
2 shared publicationsAkio Komatsu
Department of Pathology, Tama Nambu Chiiki Hospital, Japan
1 shared publication- Akio Komatsu
Tokyo Univ Sci, Dept Phys & Astron, Noda 2788510, Japan
1 shared publication
Latest Publications
- Open Access
- 15 September 2025
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64 (18) , 2813-2814
Aortitis in VEXAS Syndrome
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 15 September 2025
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64 (18) , 2813-2814
Open AccessAortitis in VEXAS Syndrome
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 16 December 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (1) , 377-384
Impact of glucocorticoids on muscle biopsy findings in antineutrophil cytoplasmic antibody-associated vasculitis
Several studies have examined the utility of quadriceps femoris muscle biopsies for diagnosing antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We aimed to investigate the effects of glucocorticoid therapy on the muscle biopsy findings of patients with AAV. Data from patients with AAV who underwent a biopsy of the bilateral vastus lateralis of the quadriceps femoris at Tokyo Metropolitan Tama Medical Center between January 2015 and December 2023 were retrospectively analyzed. In total, 126 patients with suspected small vessel vasculitis (SVV) or medium vessel vasculitis (MVV) underwent a muscle biopsy at the study center. Of these, the present study included 71 patients with a final diagnosis of AAV who received a muscle biopsy of the bilateral vastus lateralis at disease onset and began glucocorticoid therapy at the study center. Of the 71 patients, 41 (57.7%) had a positive muscle biopsy finding as defined by the presence of inflammatory infiltrates with fibrinoid necrosis in the vessels. Fifty-six and 15 patients underwent a biopsy before and after starting glucocorticoid therapy, respectively. Of the former, 33 (58.9%) had a positive finding compared to eight (53.3%) of the latter (Pearson's chi-square test: p = 0.697). Among the patients with a positive biopsy result, 22 (53.7%) and 19 (46.3%) had a unilaterally and bilaterally positive finding, respectively. Glucocorticoid therapy did not significantly affect the findings of quadriceps femoris muscle biopsies. Unilateral biopsies may have a lower diagnostic sensitivity for AAV than bilateral biopsies. Key Points • Glucocorticoid therapy does not significantly impact the results of quadriceps femoris muscle biopsies in patients with antineutrophil cytoplas¬mic antibody (ANCA)-associated vasculitis (AAV). • Unilateral biopsies may have a lower diagnostic sensitivity for AAV than bilateral biopsies.
- 16 December 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (1) , 377-384
Impact of glucocorticoids on muscle biopsy findings in antineutrophil cytoplasmic antibody-associated vasculitis
Several studies have examined the utility of quadriceps femoris muscle biopsies for diagnosing antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We aimed to investigate the effects of glucocorticoid therapy on the muscle biopsy findings of patients with AAV. Data from patients with AAV who underwent a biopsy of the bilateral vastus lateralis of the quadriceps femoris at Tokyo Metropolitan Tama Medical Center between January 2015 and December 2023 were retrospectively analyzed. In total, 126 patients with suspected small vessel vasculitis (SVV) or medium vessel vasculitis (MVV) underwent a muscle biopsy at the study center. Of these, the present study included 71 patients with a final diagnosis of AAV who received a muscle biopsy of the bilateral vastus lateralis at disease onset and began glucocorticoid therapy at the study center. Of the 71 patients, 41 (57.7%) had a positive muscle biopsy finding as defined by the presence of inflammatory infiltrates with fibrinoid necrosis in the vessels. Fifty-six and 15 patients underwent a biopsy before and after starting glucocorticoid therapy, respectively. Of the former, 33 (58.9%) had a positive finding compared to eight (53.3%) of the latter (Pearson's chi-square test: p = 0.697). Among the patients with a positive biopsy result, 22 (53.7%) and 19 (46.3%) had a unilaterally and bilaterally positive finding, respectively. Glucocorticoid therapy did not significantly affect the findings of quadriceps femoris muscle biopsies. Unilateral biopsies may have a lower diagnostic sensitivity for AAV than bilateral biopsies. Key Points • Glucocorticoid therapy does not significantly impact the results of quadriceps femoris muscle biopsies in patients with antineutrophil cytoplas¬mic antibody (ANCA)-associated vasculitis (AAV). • Unilateral biopsies may have a lower diagnostic sensitivity for AAV than bilateral biopsies.
- Open Access
- 15 June 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (12) , 1841-1842
Occipital Artery Involvement in Giant Cell Arteritis
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 15 June 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (12) , 1841-1842
Open AccessOccipital Artery Involvement in Giant Cell Arteritis
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 1 March 2023
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (5) , 811-812
SAPHO Syndrome Accompanied by Thoracic Outlet Syndrome
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 1 March 2023
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (5) , 811-812
Open AccessSAPHO Syndrome Accompanied by Thoracic Outlet Syndrome
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 2 December 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (48) , e32200
Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report
Rationale: Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome are nonmalignant but life-threatening systemic inflammatory disorders. However, many patients are refractory to treatment, resulting in significant morbidity and mortality. Additionally, established treatment options are unavailable. Therefore, we present 2 cases of adults with the iMCD-TAFRO syndrome refractory to initial treatment but responded to Janus kinase (JAK) inhibitors with ruxolitinib. The report reveals that these rare adult cases of the refractory and treatment-resistant iMCD-TAFRO syndrome can be treated using JAK inhibitors. Patient concerns: Case 1 is a 36-year-old previously healthy male patient who presented with fever and general fatigue for 2 weeks. Case 2 is a 42-year-old previously healthy female patient who presented with fever and general fatigue. Diagnosis: The diagnosis met the 2015 criteria for TAFRO syndrome, as determined by All Japan TAFRO Syndrome Research Group in the Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW) Japan. Interventions: Treatment with tocilizumab and several immunosuppressants were ineffective. So, we performed ruxolitinib. Outcomes: Each patient received ruxolitinib, the general condition improved, and CRP levels decreased. Lessons: These cases showed that ruxolitinib was effective for treatment-resistant/ refractory TAFRO syndrome. Further prospective studies are needed on using ruxolitinib with a small number of cases.
- 2 December 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (48) , e32200
Open AccessTreatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report
Rationale: Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome are nonmalignant but life-threatening systemic inflammatory disorders. However, many patients are refractory to treatment, resulting in significant morbidity and mortality. Additionally, established treatment options are unavailable. Therefore, we present 2 cases of adults with the iMCD-TAFRO syndrome refractory to initial treatment but responded to Janus kinase (JAK) inhibitors with ruxolitinib. The report reveals that these rare adult cases of the refractory and treatment-resistant iMCD-TAFRO syndrome can be treated using JAK inhibitors. Patient concerns: Case 1 is a 36-year-old previously healthy male patient who presented with fever and general fatigue for 2 weeks. Case 2 is a 42-year-old previously healthy female patient who presented with fever and general fatigue. Diagnosis: The diagnosis met the 2015 criteria for TAFRO syndrome, as determined by All Japan TAFRO Syndrome Research Group in the Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW) Japan. Interventions: Treatment with tocilizumab and several immunosuppressants were ineffective. So, we performed ruxolitinib. Outcomes: Each patient received ruxolitinib, the general condition improved, and CRP levels decreased. Lessons: These cases showed that ruxolitinib was effective for treatment-resistant/ refractory TAFRO syndrome. Further prospective studies are needed on using ruxolitinib with a small number of cases.
- 9 November 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (2) , 193-197
Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: A multicentric self-controlled case series study
- 9 November 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (2) , 193-197
Efficacy of sulfasalazine for the prevention of Pneumocystis pneumonia in patients with rheumatoid arthritis: A multicentric self-controlled case series study
- 18 January 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (8) , e252
Granulomatous vasculitis presenting as annular erythema in neurosarcoidosis
A 42-year-old woman presented with a 2-month history of annular erythema on the legs ( Fig. 1A) accompanied by ankle pain. Computed tomography revealed bilateral hilar lymphadenopathy, and Löfgren’s syndrome (LS) was suspected, but aseptic meningitis, unilateral facial palsy, and hypoalgesia of the trigeminal nerve and fourth thoracic spinal nerve developed. Skin biopsy revealed epithelioid granuloma and necrotizing vasculitis ( Fig. 1B). Neurosarcoidosis was diagnosed and she received methylprednisolone pulse therapy followed by high-dose prednisolone, which quickly alleviated her symptoms. Cutaneous sarcoidosis is categorized into specific or non-specific types depending on the presence of sarcoid granulomas [ 1]. The most common non-specific type is erythema nodosum, which often presents as part of LS with hilar adenopathy and periarthritis involving the ankles. While LS is usually self-limiting, some specific cutaneous lesions can indicate specific systemic features. Annular erythema is a rare form of cutaneous sarcoidosis, and there are...
- 18 January 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (8) , e252
Granulomatous vasculitis presenting as annular erythema in neurosarcoidosis
A 42-year-old woman presented with a 2-month history of annular erythema on the legs ( Fig. 1A) accompanied by ankle pain. Computed tomography revealed bilateral hilar lymphadenopathy, and Löfgren’s syndrome (LS) was suspected, but aseptic meningitis, unilateral facial palsy, and hypoalgesia of the trigeminal nerve and fourth thoracic spinal nerve developed. Skin biopsy revealed epithelioid granuloma and necrotizing vasculitis ( Fig. 1B). Neurosarcoidosis was diagnosed and she received methylprednisolone pulse therapy followed by high-dose prednisolone, which quickly alleviated her symptoms. Cutaneous sarcoidosis is categorized into specific or non-specific types depending on the presence of sarcoid granulomas [ 1]. The most common non-specific type is erythema nodosum, which often presents as part of LS with hilar adenopathy and periarthritis involving the ankles. While LS is usually self-limiting, some specific cutaneous lesions can indicate specific systemic features. Annular erythema is a rare form of cutaneous sarcoidosis, and there are...
- Open Access
- 1 November 2021
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 60 (21) , 3511
Late-onset COVID-19-induced Hemophagocytic Syndrome
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 1 November 2021
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 60 (21) , 3511
Open AccessLate-onset COVID-19-induced Hemophagocytic Syndrome
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 6 February 2020
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 27 (3) , e104-e105
Anti–Tumor Necrosis Factor α Therapy Induced Severe Lupus Nephritis in a Patient With Rheumatoid Arthritis
An abstract is unavailable. This article is available as a PDF only.
- 6 February 2020
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 27 (3) , e104-e105
Anti–Tumor Necrosis Factor α Therapy Induced Severe Lupus Nephritis in a Patient With Rheumatoid Arthritis
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 25 June 2019
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (1) , 112-119
Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study
Objective: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). Methods: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. Results: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation–associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). Conclusion: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.
- 25 June 2019
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (1) , 112-119
Open AccessClinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study
Objective: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). Methods: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. Results: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation–associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). Conclusion: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.